Cargando…

Targeting N17 domain as a potential therapeutic target for the treatment of Huntington disease: An opinion

Detalles Bibliográficos
Autores principales:	Kumar, Vishal, Singh, Arti
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Leibniz Research Centre for Working Environment and Human Factors 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278213/ https://www.ncbi.nlm.nih.gov/pubmed/34267617 http://dx.doi.org/10.17179/excli2021-3670

Ejemplares similares

HDAC11: A novel inflammatory biomarker in Huntington’s disease
por: Kumar, Vishal, et al.
Publicado: (2022)

Interleukin-17: A potential therapeutic target in COVID-19
por: Mendoza, Vicky M. Montaño
Publicado: (2020)

Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia
por: Dereani, Sara, et al.
Publicado: (2014)

Exploring the potential of multi-target-directed ligands for tuberculosis treatment
por: Suvvari, Tarun Kumar
Publicado: (2023)

Cyr61: a potential therapeutic target for prostate cancer
por: Lin, Chang-Ming, et al.
Publicado: (2014)

Bipolar affective disorder in Huntington's disease: A neuropsychiatric perspective
por: Raj, Rajnish, et al.
Publicado: (2015)

A rare case of Huntington's disease presenting with treatment-resistant psychosis
por: Singhai, Kartik, et al.
Publicado: (2019)

Lamin B1 and nuclear morphology in peripheral cells as new potential biomarkers to follow treatment response in Huntington's disease
por: Garcia‐Forn, Marta, et al.
Publicado: (2023)

Upper facial chorea in Huntington disease
por: Fekete, Robert, et al.
Publicado: (2014)

The First Patient with Sporadic Huntington’s Disease Due To a de Novo (CAG)n Expansion in China
por: Lin, Lishan, et al.
Publicado: (2022)

Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington’s Disease
por: Mazarei, Gelareh, et al.
Publicado: (2015)

3244 The Autonomic Nervous System as a Potential Therapeutic Target in Huntington Disease
por: Schultz, Jordan L, et al.
Publicado: (2019)

The N17 domain mitigates nuclear toxicity in a novel zebrafish Huntington’s disease model
por: Veldman, Matthew B., et al.
Publicado: (2015)

Huntington’s Disease Presenting as Adult-Onset Parkinsonism
por: Kwak, In Hee, et al.
Publicado: (2022)

Pharmacological targeting of HMGB-1 translocation: A potential therapeutic strategy for COVID-19
por: Bagheri, Vahid
Publicado: (2022)

PPARG as therapeutic target for antifibrotic therapy
por: Ghallab, Ahmed, et al.
Publicado: (2020)

Severe Acute Respiratory Syndrome–Coronavirus-2 Infection and Patients With Lung Cancer: The Potential Role of Interleukin-17 Target Therapy
por: Cafarotti, Stefano
Publicado: (2020)

The chemokine CCL17 is a novel therapeutic target for cardiovascular aging
por: Zhang, Yang, et al.
Publicado: (2023)

Modulation of nuclear REST by alternative splicing: a potential therapeutic target for Huntington's disease
por: Chen, Guo‐Lin, et al.
Publicado: (2017)

Proteomics profiling of colorectal cancer progression identifies PLOD2 as a potential therapeutic target
por: Shao, Yingkuan, et al.
Publicado: (2021)

Therapeutic Advances for Huntington’s Disease
por: Kumar, Ashok, et al.
Publicado: (2020)

Management of a patient with Huntington’s disease under spinal anaesthesia
por: Juwarkar, Sanjeev Janardan, et al.
Publicado: (2010)

Comment on “Biomarkers as Potential Treatment Targets in Inflammatory Bowel Disease: A Systematic Review”
por: Delicata, Nicholas-Paul, et al.
Publicado: (2016)

Satellite cell content in Huntington’s disease patients in response to endurance training
por: Mueller, Sandro Manuel, et al.
Publicado: (2019)

Bioinformatic gene analysis for potential therapeutic targets of Huntington’s disease in pre-symptomatic and symptomatic stage
por: Xiang, Chunchen, et al.
Publicado: (2020)

Protein Kinase CK2 and Its Potential Role as a Therapeutic Target in Huntington’s Disease
por: White, Angel, et al.
Publicado: (2022)

Metformin: From medieval age to new therapeutic targets
por: de Souza, Alexandre Leite
Publicado: (2008)

HER2 (ErbB2) receptors, a potential therapeutic target in squamous cell carcinoma of oesophagus
por: Khan, A N, et al.
Publicado: (2006)

Therapeutic potential of N-acetyl cysteine during COVID-19 epoch
por: Kapur, Ajita, et al.
Publicado: (2022)

Study on eunuchs/transgenders: An opinion
por: Peeran, Syed Wali, et al.
Publicado: (2016)

Identification of a novel therapeutic target underlying atypical manifestation of Gaucher disease
por: Kim, Eun Na, et al.
Publicado: (2022)

Reply: Her2 (ErbB2) receptors, a potential therapeutic target in squamous cell carcinoma of oesophagus?
por: Metges, J-P, et al.
Publicado: (2006)

The MID1 Protein: A Promising Therapeutic Target in Huntington’s Disease
por: Heinz, Annika, et al.
Publicado: (2021)

Mitochondria in Huntington’s disease: implications in pathogenesis and mitochondrial-targeted therapeutic strategies
por: Jurcau, Anamaria, et al.
Publicado: (2022)

WDR26 and MTF2 are therapeutic targets in multiple myeloma
por: Sun, Fumou, et al.
Publicado: (2021)

Anti-ma2 receptor encephalitis mimicking Huntington chorea
por: Etemadifar, Masoud, et al.
Publicado: (2017)

Rho GTPase-activating protein 17 (ARHGAP17) as additional autoimmune target in ARHGAP26-IgG/anti-Ca autoantibody-associated autoimmune encephalitis
por: Jarius, Sven, et al.
Publicado: (2022)

Academic Staff’s Opinion on Their Job Satisfaction
por: DIMOVA, Rositsa, et al.
Publicado: (2019)

An opinion on the impacts of COVID-19 worldwide
por: Speth, Robert C.
Publicado: (2022)

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia
por: Zabriskie, M S, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_o924hnc5kl11l8lfkeu1pnv64c